Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Conference Roundup > Pilocarpine response may predict short-term success of Kahook dual-blade goniotomy, study finds
  • Conference Roundup

Pilocarpine response may predict short-term success of Kahook dual-blade goniotomy, study finds

Kelsey Moroz

A greater reduction in intraocular pressure (IOP) following pilocarpine administration may predict short-term success with Kahook dual-blade (KDB) goniotomy at 1-month post-surgery, but this predictive value diminishes by 3 months, according to a poster presented at AAO 2024.

This prospective case series included 21 patients and measured IOP 1 hour after administering 2% pilocarpine. Surgical success was defined as either a ≥20% IOP reduction or a decrease in medication burden.

KDB was successful in 62.5% of patients at postoperative Week 1, 55.0% at 1 month, and 47.4% at 3 months. By the 3-month mark, the average IOP decreased by 3.3 mmHg from a baseline of 16.1 mmHg, with patients requiring 0.3 fewer medications. A significant correlation was found between IOP reduction from pilocarpine and KDB success at 1 month (odds ratio: 1.96), though this association diminished by 3 months.

The study concluded that while pilocarpine response may predict short-term KDB success, further research with longer follow-up is needed to clarify its long-term predictive value.

Reference
Joo JH, et al. In-Office Pilocarpine Challenge as Predictor of Goniotomy Outcome. Poster presented at: American Academy of Ophthalmology Annual Meeting; October 2024; Chicago.

Share

Related Content

  • Glaucoma

Study finds significant IOP reductions with iDose TR and MIGS procedures

  • Glaucoma

EyeValve device lowers IOP and maintains control for 9 months in first-in-human study

  • Glaucoma

GLP-1 therapies may offer potential benefits in glaucoma

  • Glaucoma

PreserFlo MicroShunt shows short-term benefit in refractory childhood glaucoma

  • Glaucoma

iStent adoption rises as surgeons treat glaucoma earlier

  • Glaucoma

Review finds low adverse event rates for glaucoma stents

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon